目的 觀察普樂(lè)安膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療慢性前列腺炎的臨床療效。方法 選取2020年4月-2022年5月鄭州大學(xué)第五附屬醫(yī)院收治的200例慢性前列腺炎患者,按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組(100例)和治療組(100例)。對(duì)照組飯后口服鹽酸坦索羅辛緩釋膠囊,1粒/次,1次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服普樂(lè)安膠囊,4~6粒/次,3次/d。兩組均治療2周。比較兩組臨床療效、病情改善狀況、尿流動(dòng)力學(xué)指標(biāo)、前列腺液細(xì)胞因子。結(jié)果 治療后,治療組的總有效率為96.00%,高于對(duì)照組總有效率85.00%(P<0.05)。治療后,兩組美國(guó)國(guó)立衛(wèi)生研究院慢性前列腺炎癥狀指數(shù)(NIH-CPSI)評(píng)分、國(guó)際前列腺癥狀評(píng)分表(IPSS)評(píng)分均顯著下降,殘余尿量減少,平均尿流率(Q_ave)、最大尿流率(Q_max)升高,前列腺液白細(xì)胞介素-6(IL-6)、腫瘤壞死因子-α(TNF-α)、前列腺素E₂(PGE₂)、白細(xì)胞介素-8(IL-8)、白細(xì)胞介素-12(IL-12)水平均顯著下降(P<0.05),且治療組病情改善狀況、尿流動(dòng)力學(xué)指標(biāo)、前列腺液細(xì)胞因子均顯著優(yōu)于對(duì)照組(P<0.05)。結(jié)論 普樂(lè)安膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療慢性前列腺炎可有效改善患者臨床癥狀和尿流動(dòng)力學(xué),減輕炎癥反應(yīng)。

Objective To observe the clinical efficacy of Pulean Capsules combine with Tamsulosin Hydrochloride Sustained-release Capsules in treatment of chronic prostatitis. Methods Patients (200 cases) with chronic prostatitis in the Fifth Affiliated Hospital of Zhengzhou University from April 2020 to May 2022 were divided into control group (100 cases) and treatment group (100 cases) according to the random number table method. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained-release Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Pulean Capsules on the basis of the control group, 4-6 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies, the improvement in condition, urodynamic indicators, and prostate fluid cytokines in two groups were compared. Results After treatment, the total effective rate of the treatment group was 96.00%, which was higher than the total effective rate of the control group of 85.00% (P < 0.05). After treatment, NIH-CPSI scores and IPSS scores of two groups were significantly decreased, the residual urine volume were decreased, but the Q_ave and Q_max were increased, the levels of IL-6, TNF-α, PGE₂, IL-8, and IL-12 in prostatic fluid of two groups were significantly decreased (P < 0.05), and the improvement in condition, urodynamic indicators, and prostate fluid cytokines of the treatment group were significantly better than those of the control group (P < 0.05). Conclusion Pulean Capsules combine with Tamsulosin Hydrochloride Sustained-release Capsules in treatment of chronic prostatitis, which can effectively improve the clinical symptoms of patients, reduce levels of inflammatory factors, and improve urodynamics.

R983

河南省高等學(xué)校重點(diǎn)科研項(xiàng)目計(jì)劃（21A320037）